Table 1.
Characteristics of Pancreatic Adenocarcinoma Patients, Including Completion of Risk Factor Questionnaire
| Not completed (N=629) | Completed (N=1,232) | Total (N=1,861) | p* | |
|---|---|---|---|---|
| Sex | 0.029 | |||
| Male | 375 (59.6%) | 669 (54.3%) | 1,044 (56.1%) | |
| Age at time of pancreatic cancer diagnosis | 0.002 | |||
| N | 629 | 1,232 | 1,861 | |
| Median | 64.0 | 67.0 | 66.0 | |
| Q1, Q3 | 56.0, 73.0 | 59.0, 74.0 | 58.0, 74.0 | |
| Vital Status | 0.164 | |||
| Alive | 102 (16.2%) | 232 (18.8%) | 334 (17.9%) | |
| Dead | 527 (83.8%) | 1,000 (81.2%) | 1,527 (82.1%) | |
| Site of Tumor | 0.943 | |||
| Head | 341 (54.6%) | 700 (57.2%) | 1,041 (56.3%) | |
| Body | 87 (13.9%) | 165 (13.5%) | 252 (13.6%) | |
| Tail | 66 (10.6%) | 116 (9.5%) | 182 (9.8%) | |
| Head & Body | 43 (6.9%) | 80 (6.5%) | 123 (6.7%) | |
| Body & Tail | 37 (5.9%) | 79 (6.5%) | 116 (6.3%) | |
| NOS | 8 (1.3%) | 16 (1.3%) | 24 (1.3%) | |
| Uncinate Process | 28 (4.5%) | 45 (3.7%) | 73 (4%) | |
| Stage Group | <0.001 | |||
| Resectable | ||||
| IA | 12 (1.9%) | 17 (1.4%) | 29 (1.6%) | |
| IB | 12 (1.9%) | 55 (4.5%) | 67 (3.6%) | |
| IIA | 28 (4.5%) | 111 (9%) | 139 (7.5%) | |
| IIB | 93 (14.8%) | 232 (18.8%) | 325 (17.5%) | |
| Locally Advanced | 246 (39.1%) | 405 (32.9%) | 651 (35%) | |
| Metastatic | 238 (37.8%) | 412 (33.4%) | 650 (34.9%) | |
| Days Survival from Diagnosis | <0.001 | |||
| N | 629 | 1,232 | 1,861 | |
| Mean (SD) | 334.4 (384.51) | 511.9 (578.95) | 451.9 (528.02) | |
| Median | 231.0 | 338.0 | 306.0 | |
| Q1, Q3 | 107.0, 426.0 | 198.5, 569.5 | 166.0, 523.0 | |
| Range | (0.0–3,797.0) | (1.0–5,899.0) | (0.0–5,899.0) | |
| Diabetes (self-reported or reported in medical record) | 0.036 | |||
| Missing | 251 | 81 | 332 | |
| No | 245 (64.8%) | 812 (70.5%) | 1,057 (69.1%) | |
| Yes | 133 (35.2%) | 339 (29.5%) | 472 (30.9%) | |
| Continuous BMI (usual adult, kg/m2) | <0.001 | |||
| N | 629 | 1,232 | 1,861 | |
| Mean (SD) | 29.4 (6.58) | 28.1 (5.37) | 28.5 (5.83) | |
| Median | 28.2 | 27.4 | 27.6 | |
| Q1, Q3 | 24.6, 32.6 | 24.4, 30.7 | 24.4, 31.2 | |
| Range | (16.4–59.0) | (15.3–53.4) | (15.3–59.0) | |
| BMI by category(usual adult, kg/m2) | <0.001 | |||
| < 18.5 | 6 (1%) | 7 (0.6%) | 13 (0.7%) | |
| 18.5–24.99 (ref) | 166 (26.4%) | 368 (29.9%) | 534 (28.7%) | |
| 25.0–29.99 | 228 (36.2%) | 493 (40%) | 721 (38.7%) | |
| 30.0–34.99 | 123 (19.6%) | 238 (19.3%) | 361 (19.4%) | |
| 35.0–39.99 | 58 (9.2%) | 80 (6.5%) | 138 (7.4%) | |
| ≥ 40.0 | 48 (7.6%) | 46 (3.7%) | 94 (5.1%) | |
| Weight Loss (as a % of usual adult weight) | <0.001 | |||
| None | 145 (23.1%) | 211 (17.1%) | 356 (19.1%) | |
| >0, ≤10 % | 255 (40.5%) | 382 (31%) | 637 (34.2%) | |
| >10% | 229 (36.4%) | 639 (51.9%) | 868 (46.6%) | |
| Categorical FBG (mg/dL) | 0.110 | |||
| Missing | 159 (%) | 259 (%) | 418 | |
| <100 | 82 (17.4%) | 133 (13.7%) | 215 (14.9%) | |
| 100–125 | 177 (37.7%) | 349 (35.9%) | 526 (36.5%) | |
| 126–150 | 85 (18.1%) | 195 (20%) | 280 (19.4%) | |
| 151–200 | 75 (16%) | 199 (20.5%) | 274 (19%) | |
| >200 | 51 (10.9%) | 97 (10%) | 148 (10.3%) | |
| Performance Score (Karnofsky) | ||||
| 90–100 | -- | 252 (26.8%) | 252 (26.8%) | -- |
| 80 | -- | 315 (33.7%) | 315 (33.7%) | |
| 70 | -- | 257 (27.5%) | 257 (27.5%) | |
| 60 | -- | 83 (8.9%) | 83 (8.9%) | |
| <50 | -- | 28 (3.0%) | 28 (3.0%) | |
BMI = Body Mass Index, FBG = Fasting blood glucose,
*
comparison of subjects who did and did not complete risk factor questionnaires